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1. Introduction 
Considerable evidence has now been accumulated 
indicating that the symptoms of Parkinsonism are 
related to a depletion of striatal dopamine. Since 
dopamine does not cross the blood-brain barrier, 
efforts to correct this deficit have focused on the 
administration of LDopa, its immediate precursor. 
Some of the principal complications of L-Dopa admi- 
nistration are related to the peripheral formation of 
catecholamines by the decarboxylation of L-Dopa. 
One refinement in its use involves administration, in
addition to Dopa, of compounds which selectively 
inhibit the metabolism of the precursor in peripheral 
tissues but not in brain. These products, which are 
peripheral Dopa-decarboxylase inhibitors and do not 
appear to pass the blood-brain barrier, should reduce 
the peripheral side effects of LDopa without inter- 
fering with its central action. Recently, since the 
purification of Dopa-decarboxylase from pig kidney 
by various authors [l-3] , considerable progress has 
been made towards the knowledge of its specificity, 
inhibition, spectral properties and the mode of binding 
of the coenzyme and the substrates [ 1,4,5] .
This paper deals with the interaction of a homo- 
geneous preparation of Dopa-decarboxylase from pig 
kidney with a compound of current interest in 
Parkinson’s disease: the L+methyl-cu-hydrazino-3,4- 
dihydroxyphenilpropionic a id (HMD). The results 
North-Holland Publishing Company - Amsterdam 
show an high affinity of the enzyme for this product 
and provide a spectral evidence of enzyme-HMD 
complex formation. 
2. Experimental 
Dopa-decarboxylase (EC 4.1.1.26) has been 
purified from pig kidney according amethod, previ- 
ously reported [3], very close to that of Lancaster 
et al. [2]. The enzyme is shown to be homogeneous 
by the criteria of disc-gel electrophoresis and ultra- 
centrifugation [6] : its specific activity is found equal 
to that previously reported [2] and its coenzyme con- 
tent [4] is in excellent agreement with Christenson 
et al. [ 11. All the compounds used were purchased 
from Sigma Chem. Co. HMD was supplied by Merck 
Sharp and Dohme. 
The assay method was by Sherald et al. [7] accord- 
ing to the modification .introduced by Charteris et al. 
[8]. Rates of decarboxylation were determined in a 
reaction mixture containing substrate and inhibitor 
in the required amounts and 0.05 M K-phosphate 
buffer, pH 6.8. The reaction was started by addition 
of the enzyme. The solutions were incubated for 5 min 
for L-Dopa and 10 min for 5hydroxy-L-tryptophan 
(LSHTP) at 25°C. One unit of enzyme activity is 
definied as the amount of protein which catalizes the 
production of 1 nmol amine/min. 
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Spectral data were obtained in a DB-CT Beckman comparison with the enzyme concentration, as gene- 
spectrophotometer connected to a Beckman 10 inch rally assumed in the classical kinetic treatments of 
recorder. enzyme inhibition. 
3. Results and discussion 
HMD is such a powerful inhibitor of pig kidney 
Dopa-decarboxylase with respect to L-Dopa and 
L-SHTP that the inhibition is observed when the 
molarities of inhibitor and enzyme are of the same 
order, as shown in fig. 1. 
Inhibition of decarboxylase activity against 
4.4 X low4 M LDopa and 4 X 10V4 M L-SHTP is also 
tested at several concentrations of enzyme at a fixed 
HMD concentration. The percent inhibition at 
0.4 X low7 M HMD concentration ranges from 
54-24% for L-Dopa and at 1.2 X 10e7 M HMD con- 
centration it ranges from 82-40% for LSHTP when 
the enzymic concentration varies from 0.35- 
1.77 X low7 M and 1.42-4.26 X 10m7 M, respectively. 
From these results it can be inferred that the degree 
of inhibition is dependent not only upon the amount 
of inhibitor but upon the amount of enzyme present: 
the percentage inhibition decreases with increasing 
enzyme concentration. These data give little informa- 
tion in terms of the mechanism of inhibition because, 
under the experimental conditions of the assay 
actually used to determine the decarboxylation rate, 
the inhibitor concentration is not greatly in excess in 
Fig. 1. Inhibition of Dopadecarboxylase activity as a function 
of inhibitor to enzyme ratio using L-Dopa (o- o), and 
L-5HTP (X - X) as substrates at 4.4 X 10“ M and 
4 X lo-’ M concentration, respectively. The concentration 
of enzyme in the assay mixtures was constant (1.42 X lo-’ M) 
in both cases. r is the molar ratio HMD/enzyme. 
It is a inhibition characterized by an enzyme- 
inhibitor complex formation theoretically reversible 
but with an apparent dissociation constant so small 
that the percent inhibition varies with the amount of 
the enzyme. Thus, at concentrations of inhibitor 
inadequate to cause complete inhibition of the enzyme, 
pratically all the inhibitor is enzyme-bound. 
Spectrophotometric studies have been carried out 
in order to investigate the interaction of HMD, even 
in absence of substrate, with Dopa-decarboxylase. 
The spectral change observed upon addition of this 
inhibitor to an enzyme solution, at pH 6.8, is charac- 
terized by a new absorption band at 395 nm whose 
intensity increases with the inhibitor binding. The 
appearance of an isosbestic point at about 435 nm 
gives evidence of a complex formation (tig.2). 
Exhaustive dialysis of 10.49 X 10m6 M enzyme 
and 9.85 X lob6 M HMD against 0.1 M K-phosphate 
buffer, pH 6.8, containing 1 X lOA M dithiotreitol 
leaves this spectrum unmodified. Spectrophotometric 
titration of enzyme with HMD has been carried out 
by using the absorption change at 395 nm as the 
criterion for complex formation. Data reported in 
the inset of fig.2 show a sharp titration curve with 
an end-point value reached at a ratio of 0.84 mol HMD/ 
mol enzyme. The same behaviour is observed when the 
titration is performed on the enzyme complexed 
with LSHTP at saturating concentration. 
Addition of substrate to an enzyme-inhibitor 
solution at a 0.84 molar ratio does not change the 
spectral properties. Spectral data show that the 
420 nm absorbing form is converted into a peak 
absorbing at 395 nm, probably due to an aldazone 
formation. The sharp titration indicates a very tight 
binding of HMD and enzyme either in absence or in 
presence of substrate. The end-point value of the 
enzyme titration does confirm the pyridoxal-P-con- 
tent, as calculated by Christenson [l] and Borri [4] . 
HMD is an excellent compound to estimate the molar 
Dopa-decarboxylase concentration of unknown 
enzymic solutions. 
The rate of formation of HMD-enzyme complex 
at 10°C is so fast that we cannot follow it, while in 
presence of LSHTP or LDopa enzyme complexes 
it is accomplished in almost 2 min. 
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Fig.2. Spectra in K-phosphate buffer, pH 6.8 (- . -) enzyme (1.85 X 10e5 M). ( -_) Enzyme plus varying HMD concentrations: 
(1) 1.26 X low6 M, (2) 2.63 X 10e6 M, (3) 3.95 X 10e6 M, (4) 5 X 10m6 M, (5) 6.64 X 10m6 M, (6) 7.85 X low6 M. (- - -) Pyri- 
doxal-P 1 X lo-’ M plus HMD 1 X 10“ M. In the inset: binding curve of HMD to the enzyme (3.55 X 10m6 M) measured by the 
changes in absorbance at 395 nm. r is the molar ratio HMD/enzyme. 
The inhibitor-enzyme complex we have observed 
is quite different from the hydrazone formed with 
free pyridoxal-P characterized by a shoulder around 
380 nm and two absorption bands at 335 nm and 
3 15 nm (ftg.2). The hydrazone formation between 
1 X lOa M HMD and 1 X IO-’ M pyridoxal-P has 
been monitored at 335 nm and a tl/,-value of 1.19 min 
was calculated. 
The high affinity of enzyme to HMD is not unex- 
pected if its chemical structure is considered. HMD 
is a compound provided with the right requirements 
for a good interaction with Dopa-decarboxylase: this 
molecule has at least three suitable points for attach- 
ment to the enzyme: a catechol ring, a carboxylic 
group and a hydrazinic one which binds to the aldei- 
die function of the coenzyme. This aldeidic group 
which exists as a Shiff base in Dopa-decarboxylase is 
more reactive (tl/, << 5 s) than the free aldeidic group 
of pyridoxal-P (flh = 1.19 min) to a nucleophilic 
attack, as already stated for glutamic-aspartic trans- 
aminase from pig heart [9]. The 420 nm absorbing 
form, attributed to a protonated Schiff base [4], 
reacts with HMD proving to be the most reactive 
species towards the carbonyl reagents, according to 
Cordes and Jencks [lo]. 
The different inhibition percentage towards LDopa 
and LSHTP (fig.1) is not easily explained: the reac- 
tion of binding of HMD to enzyme appears indeed to 
be fast as shown by the fact that a preincubation of 
enzyme with the inhibitor does not affect the activity 
towards substrates with very similar Km-values but 
different Pm, [l] . One possibility is that this behavi- 
our could be related to the enzyme’s multiplicity of 
sites where substrate and inhibitor molecules could 
bind without affecting the absorption peaks of the 
enzyme-bound pyridoxal-P, as already hypothesized 
[ 11,121. The observed lowered rate of enzyme- 
inhibitor complex formation in presence of enzyme- 
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substrate complex suggests a displacement of the 
substrate by the inhibitor, while the inhibitor, once 
combined with all the enzyme, cannot be effectively 
displaced by substrate. 
If the inhibitor affects enzyme activity to an extent 
that depends upon the enzyme concentration, when 
patients with Parkinson’s disease are given this inhibi- 
tor, a tissutal selective inhibition of decarboxylase can 
come out. A tissue containing asmall amount of Dopa- 
decarboxylase might have enzyme completely inhibit- 
ed by an inhibitor amount which would inactivate only 
a small fraction of the enzyme in tissues containing 
larger amounts of the enzyme. 
At present we do not know if therapeutic doses, 
administration times and presence of substrates in
various tissues lead to a complete or selective peripheral- 
Dopa-decarboxylase inhibition. 
Further effects on the binding of the inhibitor to 
the enzyme could be produced by other reacting 
components in tissues. All pyridoxalP enzymes are 
known to be able to interact with hydrazinic groups 
and, as we have shown, pyridoxalP reacts with HMD. 
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